Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 7.77 MB)

  Published:

  03 May 2023

• Final appraisal determination 1 committee papers (PDF 841 KB)

  Published:

  03 May 2023

• Final appraisal determination 2 committee papers (PDF 647 KB)

  Published:

  03 May 2023